Your Article Summary
See Latest ArticlesTrends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Current Medical Research and Opinion, 06/24/09
Borah BJ et al. – Study reports that etanercept (ETA) users had longer treatment duration, were more likely to adhere to their medication regimen and had lower rheumatoid arthritis (RA)-related pharmacy and RA-related total costs compared with adalimumab (ADA) users.
Methods- Main objectives of study were:
- To examine adherence to ADA and ETA and health care costs in RA pts, and
- To explore the association between adherence, utilization and costs
- RA pts treated with etanercept or adalimumab during Jan 2005-Dec 2005 were identified
- Patient adherence and costs were assessed during the 1 yr post-index period (first dispensing date)
- Nonadherence was modeled using logistic regression
- Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models
- Compared with ADA users, ETA users had longer average treatment duration
- Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA)
- Compared with ETA users, ADA users were more likely to be nonadherent
- Existing ADA users were more likely to discontinue their medication than existing ETA users
- Compared with ADA users, ETA users had lower RA-related pharmacy costs and RA-related total costs
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09
Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Current Medical Research and Opinion, 12/14/09
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Current Medical Research and Opinion, 12/11/09